4/A//SEC Filing
HIGH SUSANNA GATTI 4/A
Accession 0000950170-24-081748
CIK 0001818794other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 9:00 PM ET
Size
14.5 KB
Accession
0000950170-24-081748
Insider Transaction Report
Form 4/AAmended
HIGH SUSANNA GATTI
Chief Operating Officer
Transactions
- Sale
Common Stock
2024-06-21$35.01/sh−29,787$1,042,843→ 148,792 total - Exercise/Conversion
Common Stock
2024-06-21$5.54/sh+29,787$165,020→ 178,579 total - Exercise/Conversion
Common Stock
2024-06-24$5.54/sh+10,213$56,580→ 159,005 total - Sale
Common Stock
2024-06-24$35.33/sh−10,213$360,825→ 148,792 total - Exercise/Conversion
Stock option (right to buy)
2024-06-21−29,787→ 70,699 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (29,787 underlying) - Exercise/Conversion
Stock option (right to buy)
2024-06-24−10,213→ 60,486 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (10,213 underlying)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
- [F3]This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.63, inclusive.
- [F5]Includes 134,629 unvested RSUs.
- [F6]The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001691005
Filing Metadata
- Form type
- 4/A
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 9:00 PM ET
- Size
- 14.5 KB